Approval · Notice of Compliance 32880 · 2024
TECENTRIQ: Notice of Compliance 32880
Issued March 13, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32880
- Date
- March 13, 2024
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage regimen for the intravenous route of administration; and New subcutaneous route of administration with new formulation and strength.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
| TECENTRIQ SC | 02546310 | Marketed |
Medicinal ingredients
- ATEZOLIZUMAB 1,200 MG per 20ML
- ATEZOLIZUMAB 840 MG per 14ML
- ATEZOLIZUMAB 125 MG per ML